Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lifted by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,750 shares of the biopharmaceutical company’s stock after purchasing an additional 900 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Regeneron Pharmaceuticals were worth $4,443,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in REGN. WPG Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ:REGN opened at $612.50 on Tuesday. The stock has a market capitalization of $64.75 billion, a PE ratio of 14.92, a P/E/G ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 1 year low of $507.61 and a 1 year high of $821.11. The firm has a fifty day moving average price of $673.70 and a 200 day moving average price of $731.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the business posted $8.22 earnings per share. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Canaccord Genuity Group cut their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Finally, Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.